IN2015DN00735A - - Google Patents
Info
- Publication number
- IN2015DN00735A IN2015DN00735A IN735DEN2015A IN2015DN00735A IN 2015DN00735 A IN2015DN00735 A IN 2015DN00735A IN 735DEN2015 A IN735DEN2015 A IN 735DEN2015A IN 2015DN00735 A IN2015DN00735 A IN 2015DN00735A
- Authority
- IN
- India
- Prior art keywords
- treatment
- cancer
- formula
- derivative compound
- aromatase inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 abstract 2
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 abstract 2
- -1 urea derivative compound Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261703533P | 2012-09-20 | 2012-09-20 | |
| US201261708070P | 2012-10-01 | 2012-10-01 | |
| PCT/US2013/060292 WO2014047109A1 (en) | 2012-09-20 | 2013-09-18 | Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00735A true IN2015DN00735A (enExample) | 2015-07-10 |
Family
ID=49263471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN735DEN2015 IN2015DN00735A (enExample) | 2012-09-20 | 2013-09-18 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9532982B2 (enExample) |
| EP (1) | EP2897644B1 (enExample) |
| JP (1) | JP6212563B2 (enExample) |
| KR (1) | KR102220965B1 (enExample) |
| CN (1) | CN104661681B (enExample) |
| AU (1) | AU2013318205B2 (enExample) |
| BR (1) | BR112015004152A2 (enExample) |
| CA (1) | CA2880506C (enExample) |
| CY (1) | CY1120984T1 (enExample) |
| DK (1) | DK2897644T3 (enExample) |
| ES (1) | ES2686689T3 (enExample) |
| HR (1) | HRP20181413T1 (enExample) |
| HU (1) | HUE040520T2 (enExample) |
| IN (1) | IN2015DN00735A (enExample) |
| LT (1) | LT2897644T (enExample) |
| MX (1) | MX356278B (enExample) |
| PL (1) | PL2897644T3 (enExample) |
| PT (1) | PT2897644T (enExample) |
| RU (1) | RU2651023C2 (enExample) |
| SI (1) | SI2897644T1 (enExample) |
| WO (1) | WO2014047109A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3140427B1 (en) * | 2014-05-09 | 2020-10-14 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| CN118593514B (zh) * | 2024-05-09 | 2025-05-27 | 西南医科大学附属医院 | 芳香化酶抑制剂在制备治疗黑色素瘤药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100298286A1 (en) * | 2007-12-20 | 2010-11-25 | Novartis Ag | Organic Compounds |
| PE20091523A1 (es) * | 2007-12-20 | 2009-10-29 | Novartis Ag | Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k) |
| JP2011525535A (ja) * | 2008-06-24 | 2011-09-22 | 武田薬品工業株式会社 | ＰＩ３Ｋ／ｍＴＯＲ阻害剤 |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US8293753B2 (en) * | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
-
2013
- 2013-09-18 EP EP13770771.7A patent/EP2897644B1/en active Active
- 2013-09-18 CN CN201380049140.1A patent/CN104661681B/zh active Active
- 2013-09-18 DK DK13770771.7T patent/DK2897644T3/en active
- 2013-09-18 BR BR112015004152A patent/BR112015004152A2/pt not_active IP Right Cessation
- 2013-09-18 ES ES13770771.7T patent/ES2686689T3/es active Active
- 2013-09-18 LT LTEP13770771.7T patent/LT2897644T/lt unknown
- 2013-09-18 CA CA2880506A patent/CA2880506C/en active Active
- 2013-09-18 IN IN735DEN2015 patent/IN2015DN00735A/en unknown
- 2013-09-18 RU RU2015111171A patent/RU2651023C2/ru active
- 2013-09-18 AU AU2013318205A patent/AU2013318205B2/en active Active
- 2013-09-18 PT PT13770771T patent/PT2897644T/pt unknown
- 2013-09-18 US US14/429,367 patent/US9532982B2/en active Active
- 2013-09-18 PL PL13770771T patent/PL2897644T3/pl unknown
- 2013-09-18 HR HRP20181413TT patent/HRP20181413T1/hr unknown
- 2013-09-18 JP JP2015533141A patent/JP6212563B2/ja active Active
- 2013-09-18 MX MX2015003657A patent/MX356278B/es active IP Right Grant
- 2013-09-18 SI SI201331154T patent/SI2897644T1/sl unknown
- 2013-09-18 KR KR1020157006708A patent/KR102220965B1/ko active Active
- 2013-09-18 WO PCT/US2013/060292 patent/WO2014047109A1/en not_active Ceased
- 2013-09-18 HU HUE13770771A patent/HUE040520T2/hu unknown
-
2018
- 2018-09-05 CY CY181100927T patent/CY1120984T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015004152A2 (pt) | 2017-07-04 |
| ES2686689T3 (es) | 2018-10-19 |
| HUE040520T2 (hu) | 2019-03-28 |
| EP2897644B1 (en) | 2018-06-06 |
| RU2651023C2 (ru) | 2018-04-18 |
| MX356278B (es) | 2018-05-22 |
| JP2015532927A (ja) | 2015-11-16 |
| US20150231124A1 (en) | 2015-08-20 |
| CA2880506A1 (en) | 2014-03-27 |
| CN104661681B (zh) | 2018-07-03 |
| EP2897644A1 (en) | 2015-07-29 |
| US9532982B2 (en) | 2017-01-03 |
| KR20150056778A (ko) | 2015-05-27 |
| RU2015111171A (ru) | 2016-11-10 |
| AU2013318205A1 (en) | 2015-02-26 |
| PL2897644T3 (pl) | 2018-11-30 |
| KR102220965B1 (ko) | 2021-02-26 |
| CN104661681A (zh) | 2015-05-27 |
| MX2015003657A (es) | 2015-06-05 |
| AU2013318205B2 (en) | 2016-05-19 |
| SI2897644T1 (sl) | 2018-10-30 |
| CA2880506C (en) | 2021-04-20 |
| LT2897644T (lt) | 2018-09-25 |
| DK2897644T3 (en) | 2018-09-10 |
| HRP20181413T1 (hr) | 2018-10-19 |
| CY1120984T1 (el) | 2019-12-11 |
| WO2014047109A1 (en) | 2014-03-27 |
| JP6212563B2 (ja) | 2017-10-11 |
| PT2897644T (pt) | 2018-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| MX2021015234A (es) | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano. | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| MX2015012866A (es) | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| NZ729643A (en) | Combination therapy for treating cancer | |
| EA201690745A1 (ru) | Способы лечения и предотвращения болезни "трансплантат против хозяина" | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| BR112014023423A2 (pt) | terapia de combinação | |
| MX2014004559A (es) | Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas. | |
| EP4302825A3 (en) | Pharmaceutical compositions for treatment of inappetence | |
| MX2016001536A (es) | Derivados de urea de piperidinas. | |
| EA201390345A1 (ru) | Терапевтическое болеутоляющее средство | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| IN2015DN00735A (enExample) | ||
| BR112012025879A2 (pt) | compostos de triazol como inibidores de ksp | |
| MX366118B (es) | Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. |